AVITA Medical Inc
AVH: XASX (AUS)
| Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
|---|---|---|---|
| LOCK|R>>?!H | LOCK|s$ | LOCK|L<@>$?> |
Avita Medical: New Debt Facility Derisks Runway to Positive Cash Flow
Avita's fourth-quarter 2025 sales of USD 18 million were 3% higher than the third quarter, driven by reimbursement support stabilizing. Newly released 2026 guidance implies 15% sales growth at the midpoint. Avita has also secured a new USD 60 million debt facility. Shares rose 9%.
